作者:Bo-Tao Xin、Gisela Schimmack、Yimeng Du、Bogdan I. Florea、Gijsbert A. van der Marel、Christoph Driessen、Daniel Krappmann、Herman S. Overkleeft
DOI:10.1016/j.bmc.2016.03.035
日期:2016.8
lymphoma translocation protein 1 (Malt1) is a promising therapeutic target for the treatment of activated B cell-like diffuse large B cell lymphoma (ABC-DLBCL). Several research groups have reported on the development of Malt1 inhibitors and activity-based probes for in vitro and in situ monitoring and modulating Malt1 activity. In this paper, we report on two activity-based Malt1 probes (6 and 7) and a focused
粘膜相关淋巴组织淋巴瘤易位蛋白1(Malt1)是治疗活化的B细胞样弥漫性大B细胞淋巴瘤(ABC-DLBCL)的有希望的治疗靶标。几个研究小组已经报告了Malt1抑制剂和基于活性的探针在体外和原位监测和调节Malt1活性方面的发展。在本文中,我们报告了两种基于活性的Malt1探针(6和7)和19种新型Malt1抑制剂的重点文库。我们的基于肽的探针6以基于活性的方式标记Malt1。相反,探针7从已知的共价抑制剂MI-2衍生而来的cDNA标记了Ala突变体Malt1的野生型和无催化活性的Cys,表明MI-2通过与除活性位点半胱氨酸以外的亲核残基反应来抑制Malt1。此外,在我们基于竞争活性的蛋白谱分析中,我们的两种抑制剂(9种,表观IC 50 3.0μM ,13种,表观IC 50 2.1μM)显示出对Malt1的良好抑制活性,并优于MI-2(表观IC 50 7.8μM )。分析。